Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03791489 · ClinicalTrials.gov registry record · NA

Multi-Treatment PNN Modulation for Chronic Rhinitis

A NA study of Chronic Rhinitis, sponsored by Arrinex.

Completed
Registry status
NA
Development phase
30
Enrollment target
3
Study locations

NCT03791489: Completed NA study of Chronic Rhinitis, sponsored by Arrinex.

NCT03791489 is a NA study of Chronic Rhinitis that has completed, run by Arrinex. The registered enrollment target is 30 participants, below the 92-participant average among 6 other Chronic Rhinitis trials with a reported enrollment target (67% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03791489, a NA study of Chronic Rhinitis, has completed, sponsored by Arrinex.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

Feasibility of treatment at multiple sites with the ClariFix cryoablation device for treatment of chronic rhinitis

Primary Outcome

The outcome measure is the number of participants experiencing 1 or more SAEs/SADEs.

Conditions Studied

Interventions

  • DEVICE ClariFix

Study Locations (3)

California

  • San Francisco Otolaryngology Medical Group - San Francisco

Pennsylvania

  • Bethlehem ENT - Bethlehem

Texas

  • Tracy Byerly, MD - Fredericksburg

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-12-01
Est. Completion 2019-07-18
Phase NA
Arrinex

3 total trials

What the finished NCT03791489 record still lists

NCT03791489 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 92-participant average among 6 other Chronic Rhinitis trials with a reported enrollment target (67% lower).

The record links to 1 condition, with Chronic Rhinitis appearing as the primary indexed condition, and to 1 intervention - of which ClariFix is the first listed.

NCT03791489 reports a single indexed study location in California, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT03791489 about?

NCT03791489 is a clinical study titled "Multi-Treatment PNN Modulation for Chronic Rhinitis". Feasibility of treatment at multiple sites with the ClariFix cryoablation device for treatment of chronic rhinitis

What is the current status of trial NCT03791489?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2018-12-01. Estimated completion is 2019-07-18.

What conditions does trial NCT03791489 study?

This clinical trial studies the following conditions: Chronic Rhinitis.

What interventions are being tested in trial NCT03791489?

The interventions under investigation include: ClariFix (DEVICE).

Who is sponsoring clinical trial NCT03791489?

This trial is sponsored by Arrinex, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03791489 being conducted?

This trial has 3 study locations across California, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Rhinitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03791489, the US trial registry maintained by the National Library of Medicine. NCT03791489 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.